Choreo LLC’s Pacific Biosciences PACB Stock Holding History

Choreo LLC’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$26.7K	Buy	+11,284	New	+$15.9K	﹤0.01%	1674

Other funds holding PACB

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Capricorn Fund Managers London, United Kingdom $1.06B AUM 45.98% 1-Year Est. Return

Bourne Lent Asset Management Pawling, New York $293M AUM 24.01% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Carret Asset Management New York $1.14B AUM 25.06% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Choreo LLC's PACB Position: Q3 2026 in Review

Choreo LLC opened a new position in Pacific Biosciences (PACB) in Q3 2026: 11,284 shares worth $26.7K. The stake represents ﹤0.01% of the portfolio and ranks #1674 among its holdings.

67 funds tracked by Wall St. Rank hold PACB as of Q3 2026.

Choreo LLC held 11,284 shares of Pacific Biosciences worth $26.7K as of Q3 2026.
Pacific Biosciences was a new Choreo LLC position in Q3 2026.
Pacific Biosciences made up ﹤0.01% of Choreo LLC's portfolio in Q3 2026, its #1674 holding.
67 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2026.

Based on Choreo LLC's 13F filing for Q3 2026, filed 28 Oct 2026.